National Health (Weighted average disclosed price - second transitional disclosure cycle) Amendment Determination 2012 (No. PB 7 of 2012)

Link to law: https://www.comlaw.gov.au/Details/F2012L00655

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
National Health (Weighted average disclosed price – second transitional disclosure cycle) Amendment Determination 2012
Instrument number PB 7 of 2012
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this determination under subsection 99ADB(4) of the National Health Act 1953.
Dated  20 March 2012
 
 
 
 
 
 
 
 
 
FELICITY McNEILL
 
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
 
1              Name of Determination
       (1)     This Determination is the National Health (Weighted average disclosed price – second transitional disclosure cycle) Amendment Determination 2012.
       (2)     This Determination may also be cited as PB 7 of 2012.
2              Commencement
                This Determination commences on the day after it is registered.
 
 
3              Amendments to PB 82 of 2011
Schedule 1 amends the National Health (Weighted average disclosed price – second transitional disclosure cycle) Determination 2011 (PB 82 of 2011).
Schedule 1             Amendments
 
[1]      Schedule 1, After
 
76
Gemcitabine
Solution concentrate for I.V. infusion 500 mg (as hydrochloride) in 50 mL
Injection
Gemcitabine Ebewe
30.41
32.70
 
 
             insert:
 
76A
Gemcitabine
Solution concentrate for I.V. infusion 1g (as hydrochloride) in 25 mL
Injection
Gemcitabine Ebewe
60.81
65.38

76B
Gemcitabine
Solution concentrate for I.V. infusion 2 g (as hydrochloride) in 50 mL
Injection
Gemcitabine Ebewe
121.90
131.07

76C
Gemcitabine
Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 5 mL
Injection
Gemcitabine Ebewe
12.31
13.24

                  76D
Gemcitabine
Solution for injection 1 g (as hydrochloride) in 26.3 mL
Injection
DBL Gemcitabine Injection
 
60.81
65.38

76E
Gemcitabine
Solution for injection 2 g (as hydrochloride) in 52.6 mL
Injection
DBL Gemcitabine Injection
121.90
131.07

76F
Gemcitabine
Solution for injection 200 mg (as hydrochloride) in 5.3 mL
Injection
DBL Gemcitabine Injection
12.31
13.24

 
 
 
 
 
 
[2]      Schedule 1, After
 
96
Irinotecan
I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL
Injection
Irinotecan Actavis 500
194.45
209.07
 
 
             insert:
 
96A
Irinotecan
I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL
Injection
Tecan
194.45
209.07
 
 
Note
1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.frli.gov.au.